Second-Line Intraperitoneal Platinum-Based Therapy Leads to an Increase in Second-Line Progression-Free Survival for Epithelial Ovarian Cancer EDITORIAL COMMENT

被引：0
|
作者：
Van Le, Linda
机构：
来源：
OBSTETRICAL & GYNECOLOGICAL SURVEY | 2016年 / 71卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：468 / 469
页数：3
相关论文
共 50 条
  • [31] Progression-free and overall survival analysis in patients with metastatic melanoma undergoing first-versus second-line therapy
    Allred, J. B.
    Suman, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Second-line and subsequent therapy for ovarian carcinoma.
    Peethambaram P.P.
    Long H.J.
    Current Oncology Reports, 2002, 4 (2) : 159 - 164
  • [33] Second-line therapy for metastatic colorectal cancer
    Price, Timothy J.
    LANCET ONCOLOGY, 2015, 16 (05): : 476 - 477
  • [34] Ramucirumab: second-line therapy for gastric cancer
    Sasako, Mitsuru
    LANCET ONCOLOGY, 2014, 15 (11): : 1182 - 1184
  • [35] Second-line systemic therapy for esophageal cancer
    Martin, M. G.
    Wang-Gillam, A.
    Waqar, M. A.
    Fong, T. H.
    Gao, F.
    Govindan, R.
    Morgensztern, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Second-line hormonal therapy for prostate cancer
    Staerman, F
    EUROCANCER 2002, 2002, : 239 - 241
  • [37] Second-line Therapy for Advanced Colorectal Cancer
    Chong, Geoff
    Cunningham, David
    CURRENT COLORECTAL CANCER REPORTS, 2005, 1 (01) : 7 - 12
  • [38] Second-line therapy of metastatic bladder cancer
    Retz, M.
    Bokemeyer, C.
    ONKOLOGE, 2012, 18 (11): : 1018 - 1022
  • [39] Second-line therapy for ovarian cancer - Current standards and future trends
    Pfisterer, J
    Hilpert, F
    du Bois, A
    Meier, W
    MEDIZINISCHE WELT, 2001, 52 (05): : 133 - 136
  • [40] Topotecan as second-line therapy for ovarian cancer: Dosage versus toxicity
    Markman, M
    ONCOLOGIST, 2005, 10 (09): : 695 - 697
12345